Intravesical gemcitabine promising for TCC


Bethesda, MD-Treatment with an intravesical formulation of gemcitabine(Gemzar) in patients with transitional cell carcinoma shows promise, accordingto results from a phase I trial. The findings were presented at the Societyof Urologic Oncology/National Cancer Institute second annual meeting here.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.